Click here for an archive of Cramer's "Mad Money" recaps.
"We like companies that can reinvent themselves," Jim Cramer told viewers of his "Mad Money" TV show Monday. That's why he says he's positive on a drug maker he once hated --
Bristol-Myers has a big problem. With 50% of its drugs coming off patent protection in the next three years, most investors have lost faith in Bristol's ability to replace those lost revenues. But Cramer feels that the company does have a plan to turn around the situation, and that plan will be unveiled at Bristol's annual shareholder meeting on Tuesday.
Cramer: How to Trade This Week
var config = new Array(); config<BRACKET>"videoId"</BRACKET> = 1535093023; config<BRACKET>"playerTag"</BRACKET> = "TSCM Embedded Video Player"; config<BRACKET>"autoStart"</BRACKET> = false; config<BRACKET>"preloadBackColor"</BRACKET> = "#FFFFFF"; config<BRACKET>"useOverlayMenu"</BRACKET> = "false"; config<BRACKET>"width"</BRACKET> = 265; config<BRACKET>"height"</BRACKET> = 255; config<BRACKET>"playerId"</BRACKET> = 1243645856; createExperience(config, 8);
Cramer said that Bristol tipped its hand with the recent sale of its wound-care business, ConvaTec, for $4.1 billion. The sale, he said, gives Bristol a much needed cash boost, as does its plan to spin off 10% to 20% of its Mead Johnson baby formula business in an IPO.
With the ConvaTec sale and lofty expectations that Mead Johnson might fetch as much as $9.1 billion, Cramer expects cash-rich Bristol to start acquiring smaller drug companies to replace its waning portfolio.
Cramer also is optimistic about the future of Bristol's internal drug pipeline. He noted the company is developing promising drugs for HIV, leukemia, breast cancer, and arthritis. "The problem is that no one believes what Bristol says," said Cramer, adding all of these new drugs could be blockbusters.
Bristol-Myers' valuation is also appealing. He said the company trades at 11.4 times its earnings and an 11% long-term growth rate. The company is also aggressively cutting costs and has a "mouth-watering" 5.4% dividend yield.
Bottom line: Bristol "is just not getting enough love," he said. He believes the company is transforming itself into a pure play drug company and sees tremendous value in the process.
The Aluminum Substitution Game
"When steel prices get as high as they are, companies turn to aluminum," said Cramer.
For that reason, he's changed his mind and is now recommending
as a stock investors should own.
Alcoa currently controls 10.9% of the world's aluminum market and 19.8% of the world's raw alumina, making it the most attractive of the aluminum stocks, Cramer said.
He said aluminum is replacing the heavier and more expensive steel in industries from food packaging to autos to aerospace. And he noted China has finally worked through its excess aluminum supplies and is now once again a buyer in the global aluminum marketplace.
Cramer also identified Alcoa's fastener business as a fabulous hidden gem within the company, noting the company provides up to one million fasteners for
new 787 Dreamliner alone.
failed bid for
( RTP), Cramer said Alcoa could be a takeover target and should be valued as high as $50 to $64 a share. The company currently trades at just 10 times its earnings with a 21% long-term growth rate.
Although Alcoa has had a history and reputation of earnings missing and failed executions, he feels those legacies are behind the company.
Wrong on Google
"If there's one thing I believe in, it's accountability," Cramer told viewers. "I'm showing you where I've made my mistakes so you can learn from them."
Cramer apologized for his negative call on
, missing the company's run from $449 to $595 a share.
"Simply put, I stayed negative for too long," said Cramer. He cited four reasons for his decision. First, he relied on market data provided by Comscore, rather than doing his own homework. On Feb. 26, Comscore reported declining traffic at Google, but he said that couldn't have been further from the truth.
Second, he made the mistake of comparing Google to competitor
, reasoning that if Yahoo was shrinking, Google must be too. In reality, Google was taking share from Yahoo.
Third, he neglected to account for how quickly Google would see a return from its acquisition of DoubleClick, which, it turns out, is doing a lot better than anyone expected at this early stage.
Finally, he misjudged Google's international business growth. The company's international revenues grew at 14% this past quarter, much higher than Cramer expected.
"Now is the time to learn from my mistakes," said Cramer. With Google trading at just 23.5 times its earnings and carrying a 28% long-term growth rate, Cramer predicted Google could soon see $697 a share.
In this segment, a viewer asked Cramer about
Education and Technology Group
. Cramer said that stock is difficult to analyze and he'd stay away.
Another viewer asked about
( SGP). Cramer said he's concerned with the company's nuclear exposure domestically and its dependence on its international exposure.
Cramer was bullish on
Cramer was bearish on
North American Palladium
International Coal Group
Cramer was bullish on
Atlas Energy Resources
Cramer was bearish on
Want more Cramer? Check out Jim's rules and commandments for investing by
For more of Cramer's insights during the Lightning Round, click here
Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for
Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click
here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click
here to order his book, "Real Money: Sane Investing in an Insane World," click
here to get his second book, "You Got Screwed!" and click
here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by
TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.